【摘要】 目的 初步观察多替拉韦联合拉米夫定简化方案治疗初治HIV感染者的临床疗效。方法 采用前瞻性观察研究方法，筛选我院门诊确诊的HIV/AIDS患者，接受多替拉韦联合拉米夫定简化方案治疗，观察治疗期间CD4~+T细胞计数、CD4/CD48比值、HIV载量及炎症因子的变化情况。结果 27例患者在治疗12周时病毒抑制率为62.96%,24周和48周时分别为92.31%和100%;CD4~+T细胞计数在治疗12周时上升为（340.53±235.39）个/μl,24周时上升为（430.26±291.71）个/μl(P均<0.05)；治疗前44.44%的患者合并机会性感染，其治疗前升高的炎症因子在治疗后均逐渐下降。结论 多替拉韦联合拉米夫定简化治疗初治的HIV/AIDS患者可以获得较高的病毒抑制率，尤其可以作为晚期患者的优化方案。更多还原

【Abstract】 Objective This study aimed to evaluate the efficacy of a two-drug regimen comprising dolutegravir(DTG) and lamivudine(3TC) for the treatment of HIV infection in HAART-naive adults. Methods We performed a prospective real world study of HIV-infected patients on dolutegravir plus lamivudine regimen treatment and analysed their change of plasma HIVRNA level, CD4~+ T cell count, CD4/CD8 ratio and inflammatory factors. Results Twenty-seven antiretroviral-naive patients were enrolled. The viral suppression rate was 62.96% at week 12, 92.3% at week 24 and 100% at week 48. CD4~+ T cell count was(340.53±235.39)/μl at week 12(P <0.05)and(430.26±291.71)/μl at week 24(P <0.05). Besides, before treatment, 44.44% patients had opportunistic infectionand increased inflammatory factors which decreased after treatment. Conclusions The two-drug regimen(Dolutegravir plus lamivudine) achieved a high viral suppression rate in antiretroviral-naive adults, especially for advanced patients.更多还原